semaglutide obstructive sleep apnea trial Tirzepatide for the Treatment of and Obesity FDA approves tirzepatide to treat

A total of 31% of WEGOVY-treated patients and 27% of placebo-treated patients permanently discontinued study drug

They often overlap, which is why a medical weight loss plan should evaluate more than body weight alone

When estrogen decreases, so do those other neurochemicals, which can cause perimenopausal anxiety. Add to the mix commonly occurring stressful midlife events like financial and relationship pressures, plus career, caretaking, and the countless other energy-draining jobs that so often fall on women in their 40s and 50s (who needs a weighted vest when you carry such a heavy mental load?!)

Those on the medication on average lost 15% of their body weight in